Fusion Pharmaceuticals Inc. Retained Earnings
Fusion Pharmaceuticals Inc. had Retained Earnings of -$410.43 million as of 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2024-05-07
- 2024-03-31: Retained Earnings (Accumulated Deficit) -$410.43M.
- 2023-12-31: Retained Earnings (Accumulated Deficit) -$376.76M.
- 2023-09-30: Retained Earnings (Accumulated Deficit) -$348.58M.
- 2023-06-30: Retained Earnings (Accumulated Deficit) -$331.33M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2024-03-31 | -$410.43M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$376.76M 10-Q · filed 2024-05-07 |
| 2023-09-30 | -$348.58M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$331.33M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$306.15M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$281.86M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$257.25M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$233.23M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$214.16M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$194.25M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$177.01M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$157.59M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$130.73M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$113.20M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$99.82M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$89.83M 10-Q · filed 2020-08-11 |
| 2020-01-31 | $100.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | -$34.77M 10-K · filed 2021-03-25 |